The primary cause of death for end-stage renal disease (ESRD) patients is cardiovascular in origin with manifestations like myocardial infarction, congestive heart failure, arrhythmias, cerebrovascular accidents, and peripheral vascular disease (1, 2) . Conventional wisdom drawn from studies of subjects with normal renal function suggests that hypertension is a substantial risk factor for these complications (3) . The difficulty in controlling hypertension in the ESRD patient with pharmacologic interventions alone makes scrutiny of the dialysis prescription a priority as a principal therapeutic intervention. It is assumed that treating hypertension will have a beneficial effect on patient survival in ESRD as it does in the general population.
There are now two supportive studies that suggest a correction of hypertension in ESRD patients through increased dialysis, provided either as a thrice weekly, 8-hour, or daily 8-hour prescription, will enhance patient survival. Both studies report improved patient survival (4-6). The study by Charra et al. is especially persuasive because of its 20-year period of observation of 445 patients.
This study using the thrice weekly schedule shows a truly remarkable correction of hypertension such that 98% of a 445 patient population had normal blood pressure and discontinued antihypertensive medication within 6 months of beginning renal replacement therapy. Unadjusted mortality in this population is reported to be only 13% at 5 years as contrasted with the more general experience of 40-65% at 3 years from national registries from Europe and North America (1, 2, 4). The authors from Tassin feel that the explanation for this normalization of pressure is better sodium/volume control due to the longer duration of treatment that permits fluid removal without hemodynamic instability. In addition, they stress dietary control of salt intake.
The Toronto experience provides an interesting contrast (5, 6). The 8-hour prescription is offered 6-7 nights per week. The population reported is smaller (n=45); the period of observation is shorter (3 years); and the response to the prescription differs from that reported from Tassin in two respects. First, a lower percentage of hypertensive patients (83%) were able to stop antihypertensive medication and were normotensive at the end of 6 months. Second, they report a significant reduction in left ventricular hypertrophy; a point not reported from Tassin but noted by earlier workers as well (7) (8) (9) . Arguably, sodium and/or volume control, as explanatory interventions seem more readily achieved with the 6-7 dialysis treatments per week, especially if administered by a longer duration of treatment.
We challenge the hypothesis that alterations in salt and water are the only explanatory elements in these observational studies. Supporting this contention is a study in which normotensive patients from Tassin (n=59) were compared with hypertensive (n=28) and normotensive (n=18) patients from Stockholm who were on a 4-hour, thrice weekly treatment schedule (10) . Extracellular volume, inferior vena cava diameter and blood volume were measured among other things. A subset of the Tassin patients had objective measures of volume overload as contrasted with the Swedish normotensive group, and yet were normotensive, leading the authors to conclude that "Normotension may also be achieved in patients with fluid overload provided the dialysis time is long enough to ensure more efficient removal of one or more vasoactive factors that cause or contribute to hypertension."
Interpretative difficulties in understanding the relationship between blood pressure and survival exist. Several outcome analyses have reported the counterintuitive finding that ESRD patients with lower blood pressure are at higher risk for death than those with hypertension, i.e. a reverse "J" shaped plot of mortality vs. systolic or diastolic blood pressure (11) (12) (13) (14) . Recent additional work examining the relationship between pulse pressure (systolic minus diastolic pressure) and death risk in a large representative American ESRD cohort (n=44,000) also demonstrated an inverse correlation between mortality and systolic and diastolic blood pressure and a positive relationship with pulse pressure (15) . After adjusting pulse pressure for the degree of systolic blood pressure, the strong correlation with mortality persisted. The patient subset with the greatest
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Therapeutic use of the dialysis prescription for improvement in blood pressure control death risk was that with systolic blood pressures of less than 140 mm/Hg (15) . Pulse pressure is likely to be a measure of vascular compliance, and most ESRD patients have elevated pulse pressures. These findings suggest that this anatomic and functional abnormality in ESRD patients is of substantial clinical significance.
How then are we to reconcile these observations on the presumed salutary implications of high blood pressure and low pulse pressure with the improved outcomes reported from Tassin and Toronto?
The putative mechanism for the high cardiovascular mortality in the normotensive ESRD patient presupposes that these patients should be hypertensive, i.e., the "normal" blood pressure is reflective of a systolic or resistance vessel dysfunction. Should this speculation be valid, then a chain of logic suggests that longer dialysis treatments may result in improved cardiac function and/or reduction in the rigidity of the vascular tree. Both would have to occur to result in the reduced left ventricular hypertrophy and improved mortality reported in the Tassin and Toronto interventions.
Changes in the duration of therapy result in alterations in the solute clearance profile for the treatment rendered (16) (17) (18) . In particular, the Tassin prescription will result in an enhanced removal of larger molecular weight solutes. This "skew to the right" in the plot of solute clearance vs. molecular weight when contrasted with the conventional prescription would be even more striking for the Toronto prescription. Convective solute removal by hemofiltration similar to an increased duration of treatment also achieves a right-skewed solute clearance profile with a broader range of larger solutes removed. Early reports indicated that improved blood pressure control was part of the therapeutic response (19) . However, a single recent report in 15 subjects studied in a prospective 6-month crossover format with predilution hemofiltration and high flux hemodialysis showed a significantly higher ambulatory mean arterial blood pressure during the bracketing hemofiltration periods than during high flux hemodialysis. As noted above, this result would be compatible with the postulated pathophysiology of the observed reverse "J" shaped curve of blood pressure and mortality noted above if the broader spectrum of solutes cleared by hemofiltration and the prolonged treatment prescriptions bear an etiologic relationship to improved survival (20) .
A further point of difference between Toronto and Tassin is the increase in frequency of treatment that reduces the peak and trough solute levels that are observed in the Tassin data and that are even more pronounced than in the conventional three-hour, thrice weekly prescription. Further, the time averaged concentration of smaller solutes will be even lower for the Toronto prescription and so more nearly approximate the plasma concentrations seen with an ideal continuous high efficiency dialysis therapy, or native kidney function.
It seems that a dialysis prescription resulting in steady state reduction in uremic toxins and sodium and water levels would be the most physiologic extracorporeal treatment of ESRD. Although it is reasonable to predict better control of blood pressure and an attendant reduction in left ventricular hypertrophy (LVH) and vascular rigidity with continuous ambulatory peritoneal dialysis (CAPD), recent reports, indicate an incidence of hypertension that is not dissimilar to patients maintained on a conventional thrice weekly, 3-4 hour hemodialysis prescription. Moreover, cardiovascular death rates are generally comparable for peritoneal and hemodialysis patients (1, 2). As the sieving coefficient for sodium is about 0.6, i.e., that less sodium than water is removed with hypertonic exchanges that are glucose based (21) , it may be posited that the efficacy of ultrafiltration in normalizing sodium/volume status is limited. It is noteworthy that when a glucose polymer (icodextrin) is used in place of glucose, a set of pores with larger mean radius is engaged (22) to move sodium and water into the peritoneal space and that there is no membrane restriction to sodium transport (23) . Sodium then sieves at 1.0 as ultrafiltrate and plasma water carry identical sodium concentrations. Interestingly, a preliminary observation indicates that blood pressure control is improved when icodextrin is substituted for glucose in the CAPD prescription supporting this speculation about the etiologic role of sodium/volume in the hypertension of ESRD (24).
In conclusion, the burden of cardiovascular disease is excessive among ESRD patients and, likely also, for patients with advanced chronic kidney disease. The simple notion that hypertension in ESRD is secondary only to hypervolemia and (or) excessive total body sodium seems unlikely. Moreover, it appears that reduction of blood pressure may be accomplished by alternative dialysis regimens that may be causally associated with improved survival. It is clear that further clinical testing by intervention trials that examine classes of agents with effects on static or dynamic measures of blood pressure with and without alterations in the dialysis prescriptions are very much needed.
